© Reuters. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013 REUTERS/Robert Galbraith/Files/File Photo
(Reuters) – Johnson & Johnson (NYSE:)’s Janssen unit has sued Amgen Inc (NASDAQ:) over its plan to market an ulcerative colitis drug similar to J&J’s Stelara, saying it would infringe two patents.
Stelara is a major seller for J&J, bringing the company nearly $2.5 billion in the third quarter of 2022.
Be the first to comment